Evidence map›Paper›PMID 25024431›Full record

ArticleStem cells translational medicine2014

Selection Based on FOXA2 Expression Is Not Sufficient to Enrich for Dopamine Neurons From Human Pluripotent Stem Cells.

Julio Cesar Aguila, Alexandra Blak, Joris van Arensbergen, Amaia Sousa, Nerea Vázquez, Ariane Aduriz, Mayela Gayosso, Maria Paz Lopez Mato, Rakel Lopez de Maturana, Eva Hedlund and 2 more

Open access · goldAbstract read
In one paragraph

Article in Stem cells translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 5 countries.

Julio Cesar AguilaLaboratory of Stem Cells and Neural Repair and Cytometry and Advanced Optical Microscopy Facility, Inbiomed, San Sebastian, Spain; STEMCELL Technologies, Inc., Vancouver, British Columbia, Canada; Division of Gene Regulation, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA.
Alexandra BlakLaboratory of Stem Cells and Neural Repair and Cytometry and Advanced Optical Microscopy Facility, Inbiomed, San Sebastian, Spain; STEMCELL Technologies, Inc., Vancouver, British Columbia, Canada; Division of Gene Regulation, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA.
Joris van ArensbergenLaboratory of Stem Cells and Neural Repair and Cytometry and Advanced Optical Microscopy Facility, Inbiomed, San Sebastian, Spain; STEMCELL Technologies, Inc., Vancouver, British Columbia, Canada; Division of Gene Regulation, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA.
Amaia SousaLaboratory of Stem Cells and Neural Repair and Cytometry and Advanced Optical Microscopy Facility, Inbiomed, San Sebastian, Spain; STEMCELL Technologies, Inc., Vancouver, British Columbia, Canada; Division of Gene Regulation, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA.
Nerea VázquezLaboratory of Stem Cells and Neural Repair and Cytometry and Advanced Optical Microscopy Facility, Inbiomed, San Sebastian, Spain; STEMCELL Technologies, Inc., Vancouver, British Columbia, Canada; Division of Gene Regulation, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA.
Ariane AdurizLaboratory of Stem Cells and Neural Repair and Cytometry and Advanced Optical Microscopy Facility, Inbiomed, San Sebastian, Spain; STEMCELL Technologies, Inc., Vancouver, British Columbia, Canada; Division of Gene Regulation, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA.
Mayela GayossoLaboratory of Stem Cells and Neural Repair and Cytometry and Advanced Optical Microscopy Facility, Inbiomed, San Sebastian, Spain; STEMCELL Technologies, Inc., Vancouver, British Columbia, Canada; Division of Gene Regulation, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA.
Maria Paz Lopez MatoLaboratory of Stem Cells and Neural Repair and Cytometry and Advanced Optical Microscopy Facility, Inbiomed, San Sebastian, Spain; STEMCELL Technologies, Inc., Vancouver, British Columbia, Canada; Division of Gene Regulation, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA.
Rakel Lopez de MaturanaLaboratory of Stem Cells and Neural Repair and Cytometry and Advanced Optical Microscopy Facility, Inbiomed, San Sebastian, Spain; STEMCELL Technologies, Inc., Vancouver, British Columbia, Canada; Division of Gene Regulation, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA.
Eva HedlundLaboratory of Stem Cells and Neural Repair and Cytometry and Advanced Optical Microscopy Facility, Inbiomed, San Sebastian, Spain; STEMCELL Technologies, Inc., Vancouver, British Columbia, Canada; Division of Gene Regulation, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA.
Kai-Christian SonntagLaboratory of Stem Cells and Neural Repair and Cytometry and Advanced Optical Microscopy Facility, Inbiomed, San Sebastian, Spain; STEMCELL Technologies, Inc., Vancouver, British Columbia, Canada; Division of Gene Regulation, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA.
Rosario Sanchez-PernauteLaboratory of Stem Cells and Neural Repair and Cytometry and Advanced Optical Microscopy Facility, Inbiomed, San Sebastian, Spain; STEMCELL Technologies, Inc., Vancouver, British Columbia, Canada; Division of Gene Regulation, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA rpernaute@inbiomed.org.
Navarrabiomed · ESHarvard University · USKarolinska Institutet · SEStemcell Technologies · CAThe Netherlands Cancer Institute · NL

Funding

miRNAs as regulators of gene expression in Parkinson DiseaseR21NS067335 · NINDS · MCLEAN HOSPITAL · PI SONNTAG, KAI CHRISTIAN · 2009 to 2010
$435k
NINDS NIH HHS R21 NS067335
6 · The paper itself

Abstract

Human embryonic and induced pluripotent stem cells are potential cell sources for regenerative approaches in Parkinson disease. Inductive differentiation protocols can generate midbrain dopamine neurons but result in heterogeneous cell mixtures. Therefore, selection strategies are necessary to obtain uniform dopamine cell populations. Here, we developed a selection approach using lentivirus vectors to express green fluorescent protein under the promoter region of FOXA2, a transcription factor that is expressed in the floor plate domain that gives rise to dopamine neurons during embryogenesis. We first validated the specificity of the vectors in human cell lines against a promoterless construct. We then selected FOXA2-positive neural progenitors from several human pluripotent stem cell lines, which demonstrated a gene expression profile typical for the ventral domain of the midbrain and floor plate, but failed to enrich for dopamine neurons. To investigate whether this was due to the selection approach, we overexpressed FOXA2 in neural progenitors derived from human pluripotent stem cell lines. FOXA2 forced expression resulted in an increased expression of floor plate but not mature neuronal markers. Furthermore, selection of the FOXA2 overexpressing fraction also failed to enrich for dopamine neurons. Collectively, our results suggest that FOXA2 is not sufficient to induce a dopaminergic fate in this system. On the other hand, our study demonstrates that a combined approach of promoter activation and lentivirus vector technology can be used as a versatile tool for the selection of a defined cell population from a variety of human pluripotent stem cell lines.

Indexed as

Blotting, WesternCell SeparationDopaminergic NeuronsFlow CytometryFluorescent Antibody TechniqueGenetic VectorsGreen Fluorescent ProteinsHepatocyte Nuclear Factor 3-betaHumansLentivirusMicroscopy, ConfocalNeural Stem CellsPluripotent Stem CellsPromoter Regions, GeneticReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionFOXA2 protein, humanGreen Fluorescent ProteinsHepatocyte Nuclear Factor 3-betaCell selectionDopamineFACSFloor plateNeurogenesisPromoter

Identifiers

PMID25024431
PMCPMC4149300
OpenAlexW2010646007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.